学位：博士

职称：外籍专家老师

E-mail: ihsanullah113@gmail.com

研究方向：肿瘤代谢组学、肿瘤免疫治疗与纳米药物递送

伊山（Ihsan Ullah），男，2023年毕业于黑龙江中医药大学生药学专业，获博士学位。2024年3月至2026年5月在华南理工大学生物医学科学与工程学院从事博士后研究工作。2026年6月进入枣庄学院生命科学学院工作。主要研究方向为肿瘤代谢组学，重点开展Nano-PROTACs在肿瘤免疫治疗中的应用研究，同时围绕肿瘤微环境调控、靶向蛋白降解技术、智能纳米药物递送系统及多组学数据分析开展相关研究。近年来以第一作者、共同第一作者及参与作者身份发表SCI论文近30篇，其中以第一作者或共同第一作者身份发表论文6篇。相关成果发表于《Cancers》《Chinese Journal of Polymer Science》《Frontiers in Oncology》《Advanced Drug Delivery Reviews》 《Nature Communications》《Advanced Materials》 《Advanced Functional Materials》《ACS Nano》 etc，在肿瘤代谢组学、肿瘤免疫治疗及纳米药物递送研究领域积累了较为丰富的科研经验。

近年来发表的代表性论文（^#表示共同第一；*表示通讯作者）：

[1] Ullah, I., Yang, L., Yin, F. T., Sun, Y., Li, X. H., Li, J., & Wang, X. J. (2022). Multi-omics approaches in colorectal cancer screening and diagnosis, recent updates and future perspectives. Cancers, 14(22), 5545. #

[2] Ullah, I., Yang, W. J., Liu, Y., Chu, C. L., & Yuan, Y. (2026). Tumor Microenvironment-responsive Self-immolative Polymers for Cancer Imaging and Therapy. Chinese Journal of Polymer Science, 1-24. #

[3] Liu, Y., Ullah, I., Yuan, Y., & Wang, J. (2026). Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategies. Advanced Drug Delivery Reviews, 115776.

[4] Li, T., Zong, Q., Dong, H., Ullah, I., Pan, Z., & Yuan, Y. (2025). Non-invasive in vivo monitoring of PROTAC-mediated protein degradation using an environment-sensitive reporter. Nature Communications, 16(1), 1892.

[5] Wang, K., Jiang, M., Li, T., Liu, Y., Zong, Q., Xu, Q., Ullah, I., Chen, Y., Xue, W. and Yuan, Y., 2024. A Synergistic Chemoimmunotherapy System Leveraging PD‐L1 Blocking and Bioorthogonal Prodrug Activation. Advanced Materials, p.2402322.

[6] Jin, T., Wang, H., Ullah, I., Xie, W., Lin, T., Tan, Q., ... & Yuan, Y. (2025). A Wireless Operated Flexible Bioelectronic Microneedle Patch for Actively Controlled Transdermal Drug Delivery. Advanced Materials, 2417136.

[7] Xu, Q., Hu, X., Ullah, I., Lin, T., Liu, Y., Dong, H., ... & Wang, J. (2025). Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma. Advanced Materials, 2504253.

[8] Wang, H., Hou, Y., Lin, T., Ullah, I., Xu, Q., Liu, Y., ... & Yuan, Y. (2025). Sono‐Responsive Hydrogel for Fractionated PROTAC Release to Alleviate Resistance and Immunosuppression Induced by Multi Course Postoperative Radiotherapy. Advanced Functional Materials, e12954.

[9] Lin, T., Hou, Y., Liu, X., Ullah, I., Qiu, S., Lu, Z., ... & Yuan, Y. (2025). Fluorinated proteolysis targeting chimeras-sorafenib nanoassembly for epigenetic remodeling to combat multi-pathway drug resistance in hepatocellular carcinoma. ACS Nano, 19(39), 34659-34676.

[10] Yin, F. T., Zhou, X. H., Ullah, I., ... & Wang, X. J. (2022). Prediction of the mechanism of Dachengqi Decoction treating colorectal cancer based on the analysis method of" into serum components-action target-key pathway". J. of Ethnopharmacology, 293, 115286.

[11] Li, T., Wu, F., Zhang, A., Dong, H., Ullah, I., Lin, H., ... & Wang, X. (2022). High-throughput chinmedomics strategy discovers the quality markers and mechanisms of Wutou decoction therapeutic for rheumatoid arthritis. Frontiers in Pharmacology, 13, 854087.

[12] Xiao, K., Li, X., Ullah, I., Hu, W., Wang, K., Yang, F., ... & Li, X. (2025). Unveiling the role of ASPP1 in cancer progression: pan-cancer bioinformatics and experimental validation in colorectal cancer. Frontiers in Oncology, 14, 1529809. *

[13] Li X, Ullah I, Hou C, Liu Y, Xiao K. Network pharmacology and molecular docking study on the treatment of polycystic ovary syndrome with angelica sinensis- radix rehmanniae drug pair. Medicine, 2023; 102:46(e36118). *

[14] Xiao, K., Ullah, I., Yang, F., et al (2023). Comprehensive bioinformatics analysis of FXR1 across pan cancer: Unraveling its diagnostic, prognostic, and immunological significance. Medicine, 102(48), e36456. *

[15] Dong, H., Chu, C., Ullah, I., Xu, Q., Pan, Z., & Yuan, Y. (2026). Split‐Deliver‐Click: Tumor‐Specific Protein Degradation via “AND” Logic‐Gated In‐Cell Bioorthogonal Clicking of PROTACs. Angewandte Chemie, e20774.

[16] Zhang, X., Zong, Q., Lin, T., Ullah, I., Jiang, M., Chen, S., ... & Du, J. (2024). Self-assembled metal–phenolic network nanoparticles for delivery of a cisplatin prodrug for synergistic chemo-immunotherapy. Biomaterials Science, 12(14), 3649-3658.

[17] Ding, M., Zong, Q., Zhang, D., Ullah, I., Zhang, X., Liang, W., ... & Yuan, Y. (2024). Self-Adaptive Nanocarriers Overcome Multiple Physiological Barriers to Boosting Chemotherapy of Orthotopic Pancreatic Cancer. ACS Nano, 19(1), 662-679.

[18] Liu, Y., Zong, Q., Tu, Y., Zhang, X., Tan, Q., Ullah, I., & Yuan, Y. (2025). A Tumor Heterogeneity Independent Antigen-Responsive Nanocarrier Enabled by Bioorthogonal Pre-Targeting and Click Activated Self-Immolative Polymer. Biomaterials, 123200.

[19] Liu, Y., Wang, H., Ding, M., Yao, W., Wang, K., Ullah, I., ... & Yuan, Y. (2024). Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models. Nano Letters, 24(28), 8741-8751.

[20] Liu, X., Ullah, I., & Yuan, Y. Tumor Acidity‐Triggered Bioorthogonal Reactions for Biomedical Applications. ChemBio Chem, e202400452.1.

[21] Zheng, S., Liu, C., Chen, W., Li, N., Jiang, M., Ullah, I., ... & Li, X. (2026). Tumor-selective degradation of PARP-1 enabled by the codelivery of β-lapachone and PROTAC for non-small-cell lung cancer therapy. Nano Research, 19(1), 94908191.

[22] Li, X., Yang, C., Wang, L., Ullah, I., Xinyue, L., Feng, C., & Liu, Q. (2025). Exploring the effect and mechanism of fucoidan on liver cancer depending on network pharmacology and experimental verification. Frontiers in Chemistry, 13, 1638785.

[23] Zhao, J., Ullah, I., Fan, H., & Li, X. (2025). Epidemiological insights and clinical management of paediatric kala-azar in Shanxi Province (2014–2023): retrospective analysis of case characteristics and therapeutic strategies. BMJ Paediatrics Open, 9(1), e003131. *

[24] Meng, L. Q., Zhang, Y., Liu, C. X., Ullah, I., Zhang, T. Q., & Zhang, Y. (2025). Therapeutic potential of super activated platelet lysate (sPL) and umbilical cord mesenchymal stem cells (UCMSCs) in enhancing endometrial regeneration in rats with thin endometrium. Scientific Reports, 15(1), 24698.

[25] Liu, C., Zhang, T., Meng, L., Ullah, I., Li, H., Sui, F., & Zhang, Y. (2025). Super-activated platelet lysate promotes mesenchymal stem cell proliferation, migration, and chondrogenic differentiation: an in vitro study. Growth Factors, 43(1), 56-68.

[26] Liu, C. X., Ullah, I., & Zhang, Y. (2025). Fibroblast Growth Factor 19 (FGF-19) Expression in Glycoresistant Human Umbilical Cord Mesenchymal Stem Cells (ghUC-MSCs) and Its Regulatory Effect on Glucose Metabolism in Insulin-Resistant Hepatocytes. Dose-Response, 23(4), 15593258251412122.

[27] Ding, M., Li, H., Yang, W., Ullah, I., Chen, Z., Liu, Y., ... & Yuan, Y. (2026). Catch and light up: Dual bioorthogonal reactions actualize fluorescent probe retention and activation for surgical navigation. Biomaterials, 124236.

[28] Liu, Y., Jiang, M., Ding, M., Ullah, I., Wang, H., Xie, W., ... & Yuan, Y. (2026). PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity. Science Advances, 12(9), eado7448.

[29] Hu, X., Tan, X., Ullah, I., Jin, T., Xu, Z., Zhang, J., ... & Wang, J. (2025). Velcro-inspired poly (ethylene glycol) gel (PEGgel) for robust interface adhesion between hydrogel, device, and tissue. ACS Nano, 19(21), 20128-20143.

[30] 刘畅, 尹凤婷, IHSAN Ullah, 李晶, 李杏花, 孙晖, 闫广利, 王喜军. 基于方证代谢组学的大承气汤干预大肠癌的作用机制研究[J]. 中草药, 2025, 56 (08): 2638-2648.